Palmitoylethanolamide and its biobehavioral correlates in autism spectrum disorder: a systematic review of human and animal evidence by Colizzi, Marco et al.
nutrients
Review
Palmitoylethanolamide and Its Biobehavioral Correlates in
Autism Spectrum Disorder: A Systematic Review of Human
and Animal Evidence
Marco Colizzi 1,2,3,* , Riccardo Bortoletto 1, Rosalia Costa 4 and Leonardo Zoccante 1


Citation: Colizzi, M.; Bortoletto, R.;
Costa, R.; Zoccante, L.
Palmitoylethanolamide and Its
Biobehavioral Correlates in Autism
Spectrum Disorder: A Systematic
Review of Human and Animal
Evidence. Nutrients 2021, 13, 1346.
https://doi.org/10.3390/nu13041346
Academic Editors: Ludovica Pasca
and Pierangelo Veggiotti
Received: 17 March 2021
Accepted: 16 April 2021
Published: 18 April 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Child and Adolescent Neuropsychiatry Unit, Maternal-Child Integrated Care Department,
Integrated University Hospital of Verona, 37126 Verona, Italy; riccardo.bortoletto91@gmail.com (R.B.);
leonardo.zoccante@aovr.veneto.it (L.Z.)
2 Section of Psychiatry, Department of Neurosciences, Biomedicine and Movement Sciences,
University of Verona, 37134 Verona, Italy
3 Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience,
King’s College London, London SE5 8AF, UK
4 Community Mental Health Team, Department of Mental Health, ASST Mantova, 46100 Mantua, Italy;
rosalia.costa80@gmail.com
* Correspondence: marco.colizzi@univr.it; Tel.: +39-045-812-6832
Abstract: Autism spectrum disorder (ASD) pathophysiology is not completely understood; how-
ever, altered inflammatory response and glutamate signaling have been reported, leading to the
investigation of molecules targeting the immune-glutamatergic system in ASD treatment. Palmi-
toylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to
be effective in controlling inflammation, depression, epilepsy, and pain, possibly through a neuro-
protective role against glutamate toxicity. Here, we systematically reviewed all human and animal
studies examining PEA and its biobehavioral correlates in ASD. Studies indicate altered serum/brain
levels of PEA and other endocannabinoids (ECBs)/acylethanolamines (AEs) in ASD. Altered PEA
signaling response to social exposure and altered expression/activity of enzymes responsible for
the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator
activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have
been reported. Stress and exposure to exogenous cannabinoids may modulate ECBs/AEs levels and
expression of candidate genes for neuropsychiatric disorders, with implications for ASD. Limited
research suggests that PEA supplementation reduces overall autism severity by improving language
and social and nonsocial behaviors. Potential neurobiological underpinnings include modulation
of immune response, neuroinflammation, neurotrophy, apoptosis, neurogenesis, neuroplasticity,
neurodegeneration, mitochondrial function, and microbiota activity, possibly through peroxisome
proliferator-activated receptor-α (PPAR-α) activation.
Keywords: neurodevelopment; pervasive developmental disorder; cannabinoids; acylethanolamines;
immune response; glutamate; inflammation; peroxisome proliferator-activated receptor-α; child and
adolescent neuropsychiatry
1. Introduction
Autism spectrum disorder (ASD) is a complex and multifactorial neurodevelopmental
condition affecting those who suffer from it at different levels. Difficulties in social commu-
nication and associated tendency to have restrictive interests and repetitive and stereotyped
activities are considered the core aspects of the disorder [1], allowing clinicians to make
a diagnosis of ASD based on behavioral assessment [2]. However, converging research
evidence supports the presence of altered neurobiological parameters such as functional
and structural brain abnormalities [3,4], by which gene variants or epigenetic marks lead
to the neurocognitive and biobehavioral symptoms consistently reported in ASD [5,6]. It is
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noteworthy that, even though the pathophysiology of ASD is not completely understood,
studies conducted over the last two decades have helped clarify some of the mechanisms
of disease progression. In particular, altered inflammatory response [7] and disrupted
glutamate signaling [8–10] have been reported, leading the way to the investigation of
the effect of molecules targeting the immune-glutamatergic system in improving clinical
severity in ASD [11].
Growing evidence indicates that one of the major physiological functions of the
cannabinoid signaling system is the modulation of neuroinflammation [12] and glutamate
neurotransmission [13]. Both exogenous cannabinoids (e.g., plant-derived cannabinoids ∆9-
tetrahydrocannabinol, ∆9-THC, and cannabidiol, CBD) and their endogenous counterparts
(e.g., endocannabinoids anandamide and 2-arachidonoylglycerol, 2-AG) interact with the
endocannabinoid system, with implications for health and disease [14,15]. Despite promis-
ing evidence on the efficacy of ∆9-THC- and CBD-based treatments in the management of
ASD-related behavioral problems, it is still limited and requires further investigation [16].
Anandamide (arachidonoylethanolamide) and 2-AG are both derivatives of arachidonic
acid, a polyunsaturated fatty acid well known as the precursor of bioactive prostaglandins
and other eicosanoids, with anandamide specifically being its ethanolamine [17].
Other ethanolamines of various long-chain fatty acids also naturally occur, and along
with anandamide they are collectively referred to as N-acylethanolamines. However, they
are more abundant than anandamide in the body and do not bind to cannabinoid receptors,
while exerting most of their biological effects by activating the peroxisome proliferator-
activated receptor-α (PPAR-α), a nuclear receptor, and PPAR-α-independent pathways
involving other receptors such as Transient Receptor Potential Vanilloid 1 (TRPV1) and
GPR55 [17,18]. Research evidence suggests that such specific mechanisms of action would
account for their anti-inflammatory, analgesic, anticonvulsant, and neuroprotective proper-
ties [17,18]. Palmitoylethanolamide (PEA, N-hexadecanoylethanolamide), in particular, is
a saturated N-acylethanolamine which has been suggested to be effective in the control of
inflammatory responses [19,20], depressive symptoms [21], epilepsy [22], and pain [23],
possibly through a neuroprotective role against glutamate toxicity [17].
Objectives
This effect of PEA on (neuro)inflammation and glutamate signaling could repre-
sent a promising neurobiological mechanism underlying the clinical utility of such N-
acylethanolamine in ASD. This review aims to bring together and discuss all available
data generated by clinical and preclinical studies investigating the role of PEA in ASD by
conducting a systematic literature search for all such data. We reviewed all interventional
and observational studies, employing either retrospective or prospective methodological
approaches with any PEA biobehavioral correlates investigated in ASD.
2. Experimental Procedures
2.1. Inclusion and Exclusion Criteria
To summarize previous research evidence on the topic, inclusion criteria for studies
were: (1) human or animal studies, (2) studies investigating both the acute and long-term
effects of palmitoylethanolamide (PEA) administration in autism spectrum disorder (ASD)
and related conditions, (3) studies investigating PEA signaling-related molecular markers
in ASD and related conditions, including (a) blood serum levels, (b) brain tissue levels,
(c) enzyme activity, and (d) receptors. Exclusion criteria were (1) studies where PEA was not
the intervention of interest (i.e., studies evaluating only exogenous cannabinoid agonists or
antagonists), (2) studies where PEA biobehavioral correlates were not investigated with
reference to ASD, and (3) studies in which the PEA biobehavioral correlates were not
directly reported on.
Nutrients 2021, 13, 1346 3 of 15
2.2. Search Strategy and Data Extraction
A literature search was conducted using electronic databases (MEDLINE, Web of Sci-
ence and Scopus) for any published original study written in English, using a combina-
tion of search terms describing autism (‘autism spectrum disorder,’ ‘Asperger syndrome,’
‘pervasive developmental disorder,’) and palmitoylethanolamide (‘palmitoylethanolamide,’
‘palmitylethanolamide’, ‘N-(2-hydroxyethyl)hexadecanamide’, ‘N-(2-hydroxyethyl)palmitate’,
‘N-palmitoylethanolamine’) on 3 March 2021. Reference lists of eligible studies were also
screened to identify additional eligible research. Publication data screening and extraction were
performed following a 2-step selection process (conventional double-screening) conducted by
2 reviewers independently of each other (MC and RB).
2.3. Risk of Bias
The methodological heterogeneity of the studies (Table 1) included in this review
necessitate a suitably inclusive and flexible approach to assess risk of bias and study
quality. Thus, we used an adapted set of criteria suggested by the Agency for Healthcare
Research and Quality (AHRQ) guidance [24], amended as appropriate for interventional
and observational studies in humans (Table 2). Risk of systematic bias across human studies
was additionally assessed by screening all papers for potential confounding variables such
as comorbid psychiatric conditions and substance use (Table 2). Further, to assess any factor
that may account for similarities and differences between animal studies, information was
extracted about study characteristics, including animal model (e.g., mouse or rat), autism
model (e.g., valproic acid, perinatal asphyxia, strain of idiopathic autism), developmental
stage (i.e., prenatal or postnatal), sex, and PEA dosage (Table 3).
3. Results
3.1. Study Selection
In summary, 53 records were retrieved. Abstracts of all records were screened against
the inclusion and exclusion criteria. After also excluding duplications (Figure 1), a final list
of 10 studies (3 human, 6 animal, 1 using both humans and animals) was used for systematic
analysis in this review (Table 1). In total, the eligible studies assessed different aspects of
the palmitoylethanolamide (PEA) signaling pathway (Table 1). These include (1) in vivo
PEA treatment exposure in human(s) with autism spectrum disorder by employing a
monotherapy design (ASD; two studies; Table 2); (2) in vivo PEA treatment exposure
in human(s) with ASD by employing an add-on design (one study; Table 2); (3) PEA
quantitative blood assessment in human(s) with ASD (one study; Table 2); (4) in vivo PEA
postnatal exposure in animal models of autism (two studies; Table 3); (5) in vivo PEA
postnatal exposure in animal models of perinatal brain disorders (two studies; Table 3);
(6) PEA quantitative brain assessment in animal models of autism (one study; Table 3);
(7) PEA quantitative brain assessment in animal models of stress following exposure to
exogenous cannabinoid agonists/antagonists (one study; Table 3); (8) PEA-related enzymes
and receptors quantitative brain assessment in animal models of perinatal brain disorders
(one study; Table 3). Additional data on methodological quality of studies conducted in
humans and animals are reported in Tables 2 and 3. A brief synthesis of the main results is
presented below.
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Table 1. Summary of studies investigating palmitoylethanolamide and its biobehavioral correlates in autism spectrum disorder.
Study
(Country) Aim of Study PEA Type of Study Population N
Outcome Measure
(Test Name or Description) Results
Antonucci et al.
(2015) (Italy)






exposure in humans 2 ASD adolescents 2
1. Expressive language (MLU); 2.
overall autism severity (CARS-2;
ATEC); 3. immune response
(blood tests)
1. MLU: ↑ from 3.0 to 5.4; 2. CARS-2 test: ↓ from 43.5
to 32, ATEC: ↓ from 25 to 12; 3. vitamin D-OH25 level:
↑, CD57+ NK: ↑, total lymphocytes: ↓, total serum IgE:
↓ by ~50% (only in 1 case, in the other case NS), atopic
illnesses: ↓, total WC: unchanged
Aran et al.
(2019) (Israel)







1. 93 ASD chil-
dren/adolescents; 2.
93 HCs
186 Serum ECBs/AEs levels(LC-MS/MS)
1. Serum levels of AEA, OEA and PEA: ASD < HC
(after Bonferroni correction, still significant), 2-AG:
ASD vs. HC, NS; 2. ↓ age or ↓ BMI: ↓serum levels of
AEA (after Bonferroni correction, NS; correlations
with other ECBs/AEs, NS); 3. ↑ APSI severity score
or ↑ use of antipsychotics: ↓ serum levels of AEA
(trend effect; correlations with other ECBs/AEs
and/or other symptoms, NS)
Bertolino et al.
(2016) (Italy)
To assess the effect
of PEA on behavior
In vivo treatment
exposure in humans 1 ASD child 1
1. Overall autism severity (ATEC);
2. Motor stereotypic behaviors
(Quarterly questionnaire)
1. ATEC: ↓ of both total and subgroup scores (Speech,
Sociability, Sensory/Cognitive,
Health/Physical/Behavior; improved of about 23%); 2.




To assess the effect






1. 31 ASD (Arm A,
risperidone + PEA);
2. 31 ASD children








1. ABC-C over time: irritability and hyperactivity,
risperidone + PEA < risperidone + placebo (other
domains NS); 2. ABC-C at 10 weeks: irritability,
hyperactivity, and inappropriate speech (trend),
risperidone + PEA < risperidone + placebo (other
domains NS); 3. ABC-C at 5 weeks: hyperactivity,
stereotypic behavior (trend), and inappropriate
speech (trend), risperidone + PEA < risperidone +
placebo (other domains NS); 4. ABC-C response rate
at 10 weeks, hyperactivity, irritability, and
inappropriate speech, risperidone + PEA >
risperidone + placebo (other domains NS); 5. ABC-C
response rate at 5 weeks, NS; Adverse events, NS
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Table 1. Cont.
Study
(Country) Aim of Study PEA Type of Study Population N
Outcome Measure
(Test Name or Description) Results
Bertolino et al.
(2016) (Italy)
To assess the effect







1. 60 SHAM+VHI; 2.










IL-1β); Western Blot (Bax, Bcl-2,
iNOS, IкBα, NF-kB, GFAP);
Neurogenesis (BrdU and DCX
Immunohistochemistry and Golgi
impregnation))
1. SIT: stay duration in stranger side, VPA <
VPA+PEA; stay duration in central area, VPA >
VPA+PEA; SI, VPA < VPA+PEA; EPM: time spent in
the open arm, VPA < VPA+PEA; 2. chymase,
tryptase, IL-1 and TNF-α expression to mast cells in
hippocampus and cerebellum: VPA > VPA+PEA;
iNOS and GFAP levels in hippocampus and
cerebellum: VPA > VPA+PEA; IкBα and NF-kB
levels: VPA < VPA+PEA; Bax: VPA > VPA+PEA;
Bcl-2: VPA < VPA+PEA; BrdU+ cells, DCX+ cells
and development of dendritic spines in the dentate
gyrus of hippocampus: VPA < VPA+PEA
Kerr et al.
(2013) (Ireland)











1. 16 saline; 2. 14
VPA 30
1. Brain ECBs/AEs levels
(LC-MS/MS); 2. behavior
(sociability test); 3. gene
expression (real-time PCR); 4.
enzyme activity
1. AEA, 2-AG, PEA and OEA in frontal cortex,
hippocampus and cerebellum: VPA vs. saline NS; 2.
AEA, OEA and PEA in hippocampus after
sociability test: VPA > saline (other ECBs in other
brain regions NS); 3. MAGL mRNA in the
hippocampus, DAGLα mRNA in the cerebellum,
VPA < saline (other brain region NS); PPARα and
PPARγ mRNA in frontal cortex and hippocampus,
VPA < saline; GPR55 mRNA in frontal cortex and
hippocampus, VPA < saline (cerebellum NS);
CB1/CB2 receptor mRNA in frontal cortex,
hippocampus and cerebellum, VPA vs. saline, NS; 4.














enzyme and receptor activity
(immunohistochemistry,
immunostaining quantification)
1. NeuN: NS; GFAP-positive cells: PA > CTL and C+
in CA1, CA3, and DG regions of dorsal
hippocampus; DAGLα expression: PA and C+ >
CTL in CA1, C+ > CTL in DG (other regions or
groups NS); NAPE-PLD expression: PA < C+ and
CTL in CA1 and CA3, PA < C+ in DG (other regions
or groups NS); CB1 expression, NS; PPARα-positive
cells: PA < C+ and CTL in CA1 and CA3 (DG NS);
FAAH expression: C+ > CTL and PA in CA3 (other
regions or groups NS)
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Table 1. Cont.
Study
(Country) Aim of Study PEA Type of Study Population N
Outcome Measure
(Test Name or Description) Results
Herrera et al.
(2018) (Spain)
To assess the effect





1. 15 PA+VHI; 2. 13









Western Blot (pNF H/M, MAP-2,
GFAP))
1. OFT: time spent rearing, PA < CTL, PA < PA+PEA,
CTL vs. PA+PEA NS, CTL vs. CTL+PEA NS; time
spent grooming, PA > CTL, PA > PA+PEA, CTL vs.
PA+PEA NS, CTL vs. CTL+PEA NS; EPM: time spent
rearing, PA < CTL, PA < PA+PEA, CTL vs. PA+PEA
NS, CTL vs. CTL+PEA NS; time spent grooming, PA
> CTL, PA vs. PA+PEA NS, PA+PEA > CTL; time
spent HD, PA > CTL, PA > PA+PEA, CTL vs.
PA+PEA NS, CTL vs. CTL+PEA NS; 2. pyknotic
nucleus in the hippocampal CA1 neurons: PA >
CTL, ↓ in PA+PEA; NeuN abnormal neurons in the
hippocampal CA1 layer: PA > CTL, ↓ in PA+PEA;
hippocampal pNF-H/M reactive area/ protein
expression: PA > CTL, ↓in PA+PEA (PA+PEA still >
CTL); hippocampal MAP-2reactive area/ protein
expression: PA < CTL, ↑ in PA+PEA (PA+PEA still <
CTL); GFAP-positive cells and protein expression: NS
Cristiano et al.
(2018) (Italy)
To assess the effect



























1. Behavior (MBA, SGT, TST); 2.
gene expression, receptor activity,
neurotrophins (Western Blot,





axis (intestinal permeability assay
(FITC-labeled dextran, faecal
microbiota))
1. MBA and SGT: BTBR > B6, BTBR+PEA10 ↓,
BTBR+PEA30 ↓↓, BTBR+GW+PEA vs. BTBR NS,
BTBR+GW vs. BTBR NS, KO+PEA vs. KO NS; TST:
BTBR+PEA10 ↑, BTBR+PEA30 ↑↑, BTBR+GW+PEA
vs. BTBR NS, BTBR+GW vs. BTBR NS, KO+PEA vs.
KO NS; BTBR+PEA30 early (1h) effect NS; B6+PEA vs.
B6 NS; 2. PPAR-α mRNA and protein, BDNF
protein, TrkB mRNA, CREB protein (CREB mRNA
NS): BTBR < B6, BTBR+PEA30 ↑; 3. mitochondrial
state 3 respiration and SOD activity: BTBR < B6,
BTBR+PEA ↑ (mitochondrial state 4 respiration and
oligomycin state 4 respiration NS); FCCP-stimulated
respiration, mitochondrial energetic efficiency, ROS:
BTBR+PEA ↓; TNFα, IL1-β, IL6 in hippocampus,
colon and serum: BTBR > B6, BTBR+PEA ↓; 4.
epithelial barrier integrity (Tjp1 and Ocln mRNA
levels): BTBR < B6, BTBR+PEA ↑; Microbial
community: Firmicutes/Bacteroidetes ratio,
BTBR+PEA > BTBR
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Table 1. Cont.
Study
(Country) Aim of Study PEA Type of Study Population N
Outcome Measure














1. 60 STS; 2. 60 CTL;












1. Behavior (FOB, OFT); 2. brain
ECBs/AEs and related gene
expression (LC-APCI-MS,
real-time PCR)
1. Effect of stress: AEA levels in dorsal CPu, STS <
CTL; Chrna6 gene expression, STS > CTL; 2. Effect
of drugs exposure: OFT, distance travelled,
WIN+VHI < VHI, Rim+WIN < Rim+VHI; distance
travelled in center, Rim+VHI > WIN+VHI; rearing
activity, Rim+WIN > WIN+VHI; PEA and OEA
levels in dorsal Cpu, WIN+VHI > others; Fkpb5
expression, Rim+WIN > others; 3. Effect of stress
under drug influence: OFT, distance travelled,
STS+VHI > CTL+VHI, STS/CTL+WIN+VHI <
STS/CTL+Rim+VHI, STS+WIN+VHI < STS+VHI,





STS+WIN+VHI/CTL groups; Slc6a4 gene




To assess the effect




1. 15 PA+VHI; 2. 13












1. Striatal pNF-H/M reactive area/protein
expression: PA < CTL, ↑ in PA+PEA (PA+PEA still <
CTL); striatal MAP-2 reactive area/protein
expression: PA < CTL, ↑ in PA+PEA; GFAP-positive
cells: PA < CTL, ↑ in PA+PEA (PA+PEA still < CTL;
protein expression NS)
PEA, Palmitoylethanolamide; ASD, Autism Spectrum Disorder; MLU, Mean Length of Utterance; CARS-2, Childhood Autism Rating Scale-Second Edition; ATEC, Autism Treatment Evaluation Checklist;
25(OH)D3, 25-hydroxyvitamin D3; NK, Natural Killer cells; IgE, Immunoglobulin E; NS, Not Significant; WCs, White Cells; ECBs, Endocannabinoids; HCs, Healthy Controls; LC–MS/MS, Liquid Chromatography–
Mass Spectrometry; AEA, Arachidonoylethanolamide; OEA, Oleoylethanolamide; 2-AG, 2-arachidonoyglycerol; BMI, Body Mass Index; APSI, Autism Parenting Stress Index; ABC-C, Aberrant Behavior
Checklist-Community; VPA, Valproate; SIT, Social Interaction Test; EPM, Elevated Plus Maze; TNF-α, Tumor Necrosis Factor alpha; IL-1β, Interleukin 1 beta; Bax, BCL2-Associated X protein; Bcl-2, B-cell
lymphoma 2; iNOS, inducible Nitric Oxide Synthase; IкBα, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B
cells; GFAP, Glial Fibrillary Acidic Protein; BrdU, Bromodeoxyuridine; DCX, Doublecortin; AEs, acylethanolamines; PCR, Polymerase Chain Reaction; MAGL, Monoacylglycerol lipase; mRNA, Messenger
Ribonucleic Acid; DAGLα, Diacylglycerol lipase α; PPARα, Peroxisome Proliferator-Activated Receptor alpha; PPARγ, Peroxisome Proliferator-Activated Receptor gamma; GPR55, G protein-coupled receptor 55;
CB1, Cannabinoid receptor type 1; CB2, Cannabinoid receptor type 2; FAAH, Fatty Acid Amide Hydrolase; CTL, control group; C+, cesarean section group; PA, Perinatal Asphyxia; CA1, Cornu Ammonis-1; CA3,
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Cornu Ammonis-3; DG, Dentate Gyrus; NAPE-PLD, N-acyl phosphatidylethanolamine phospholipase D; OFT, Open Field Test; NeuN, Hexaribonucleotide Binding Protein-3; pNF-H/M, Phosphorylated
Neurofilament H; MAP-2, Microtubule-associated protein 2; HD, Head dipping; GW, GW6471 (N-((2S)-2-(((1Z)-1-Methyl-3-oxo-3-(4-(trifluoromethyl)phenyl)prop-1-enyl) amino)-3-(4-(2-(5-methyl-2-phenyl-1,3-
oxazol-4-yl)ethoxy)phenyl)propyl) propanamide); MBA, Marble Burying Assay; SGT, Self-Grooming Test; TST, Three-chambered Social Test; FITC, Fluorescein Isothiocyanate; PEA10, Palmitoylethanolamide
10 mg/Kg; PEA30, Palmitoylethanolamide 30 mg/Kg; 1h, one hour; BDNF, Brain-Derived Neurotrophic Factor; TrkB, Tropomyosin receptor kinase B; CREB, cAMP response element-binding protein; SOD,
Superoxide Dismutase; FCCP, Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone; ROS, Reactive Oxygen Species; IL6, Interleukin 6; Tjp1, Tight junction protein 1; Ocln, Occludin; STS, stress; WIN,
CB1/CB2 receptor agonist WIN55212.2; Rim, selective cannabinoid CB1 receptor antagonist Rimonabant; FOB, Functional Observational Battery; LC–APCI–MS, liquid chromatography–atmospheric pressure
chemical ionization–mass spectrometry; Cpu, caudate-putamen; Chrna6, Cholinergic Receptor Nicotinic Alpha 6; Fkpb5, FKBP Prolyl Isomerase 5; Slc6a4, Solute Carrier Family 6 Member 4; bold font emphasizes
statistically significant results.
Table 2. Methodological quality of human studies investigating palmitoylethanolamide and its biobehavioral correlates in autism spectrum disorder.
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Table 2. Cont.








































































































Mg, milligrams; NA, not applicable; ADOS-2, Autism Diagnostic Observatory Schedule Second Edition; DSM-5, Diagnostic and Statistical Manual of Mental Disorders fifth edition; VABS-II, Vineland Adaptive
Behavior Scale Second Edition; SCQ, Social Communication Questionnaire; CARS2-ST, Childhood Autism Rating Scale-second edition; HSQ-ASD, Home Situations Questionnaire-Autism Spectrum Disorder;
CBCL, Child Behavior Checklist; APSI, Autism Parenting Stress Index; SRS-2, Social Responsiveness Scale-II; CGI-S, Clinical Global Impression-Severity; SD, standard deviation; HCs, healthy controls; ASD,
Autism Spectrum Disorder; BMI, Body Mass Index; ADHD, Attention Deficit Hyperactivity Disorder; co-ultraPEA-Lut, ultramicronized Palmitoylethanolamide with Luteolin; ABC-C, Aberrant Behavior
Checklist Community; PEA, Palmitoylethanolamide; ESRS, Extrapyramidal Symptom Rating Scale; ANOVA, Analysis of Variance; ITT, intention-to-treat.
Table 3. Methodological quality of animal studies investigating palmitoylethanolamide and its biobehavioral correlates in autism spectrum disorder.
Study Study Design Defined StudyPopulation Age Gender PEA Measure
Adequate PEA









































and post hoc Tukey tests with
Bonferroni correction for multiple
comparisons; all other results:





























Shapiro–Wilk test; Levene test;
unpaired t-test
√
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Table 3. Cont.
Study Study Design Defined StudyPopulation Age Gender PEA Measure
Adequate PEA























































































































































VPA, Valproate; mg/kg, milligrams per kilogram; SC, subcutaneously; P, postnatal day 14; P15, postnatal day 15; P120, postnatal day 120; co-ultraPEA-Lut, ultramicronized Palmitoylethanolamide with
Luteolin; PEA, Palmitoylethanolamide; ANOVA, Analysis of Variance; G12.5, gestational day 12.5; P33, postnatal day 33; P40, postnatal day 40; PA, Perinatal Asphyxia; P30, postnatal day 30; CTL, control
group; C+, cesarean section group; 1st h, first hour; IP, intraperitoneal; GW, GW6471 (N-((2S)-2-(((1Z)-1-Methyl-3-oxo-3-(4-(trifluoromethyl)phenyl)prop-1-enyl) amino)-3-(4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-
yl)ethoxy)phenyl)propyl) propanamide); h/day, hour per day.
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Three studies have addressed this area in humans, including two case reports of two 
adolescents [25] and one child [26] with ASD as well as a double-blind, randomized (par-
allel), placebo-controlled trial performed among 62 risperidone-treated ASD children [27]. 
These studies have assessed the effects of PEA treatment on language [25,27], behavior 
[25–27] and additional parameters. The two case reports indicated that PEA supplemen-
tation improves expressive language [25] and reduces overall autism severity [25,26], in-
cluding motor stereotypic behaviors [26], appearing to be beneficial also in modulating 
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3.2. In Vivo PEA Treatment Exposure in Children and Adolescents with Autism
Spectrum Disorder
Thre studie have addressed this area in humans, including two case reports of
two a lescents 5 and one child [26] with ASD as well as a double-blind, random-
ized (parallel), lacebo-controlled trial performed mong 62 risperidone-treated ASD
c ildren [27]. Thes studies have assessed the effects of PEA treatment on language [25,27],
behavior [25–27] and additional parameters. The two case reports indicated that PEA
supplementatio improves expressive language [25] and reduces overall autism sever-
ity [25,26], including motor stereotypic behaviors [26], appearing to be beneficial also in
modulating immune chemistry [25] and controlling enuresis [26]. The trial of PEA add-on
to risperidone reported significant improvements in the domains of irritability and hyper-
activity among ASD children receiving the combination treatment of risperidone and PEA
as compared to those receiving only risperidone, with weak effects of PEA add-on also in
reducing stereotypic behavior and inappropriate speech [27].
3.3. PEA Levels in Children and Adolescents with Autism Spectrum Disorder as Compared to
Healthy Controls
This systematic review identified a single study specifically investigating whether
ASD children and adolescents differ from their healthy peers in terms of circulating blood
levels of PEA and other endocannabinoids (ECBs)/acylethanolamines (AEs). This study
found that ASD children and adolescents have lower serum levels of PEA and other
ECBs/AEs as compared to healthy controls. Additionally, PEA levels did not appear to
change as a function of any sociodemographic and clinical characteristics [28].
3.4. In Vivo PEA Postnatal Exposure in Animal Models of Autism and Perinatal Brain Disorders
All these studies investigated the effect of PEA exposure, using similar but not over-
lapping methodologies in terms of animal type (mice [26,29], rat [30,31]), mode of adminis-
tration (oral [26], subcutaneous [30,31], intraperitoneal [29]), period of exposure (postnatal
day P15 to P120), dosage of PEA (1 to 30 mg/kg), and model of pathology (valproic acid
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(VPA) exposure [26], perinatal asphyxia (PA) [30,31], BTBR T+tf/J strain (BTBR) [29]). The
first of these studies indicated that PEA administration improves social and nonsocial
behaviors, reduces the expression of proinflammatory markers, modulates apoptosis in
the hippocampus and cerebellum, and increases hippocampal neurogenesis and neuro-
plasticity in the VPA-induced rodent model of autism [26]. Another study found that
PEA administration reverts the altered social and nonsocial behavioral phenotype in the
inbred BTBR strain used as mice model of autism, possibly by reducing the expression
of pro-inflammatory markers, activating the peroxisome proliferator-activated receptor-α
(PPAR-α), and restoring hippocampal brain derived neurotrophic factor (BDNF) signaling,
mitochondrial function, and microbiota composition [29]. Subsequent studies investigated
the potential neuroprotective role of PEA in the PA rat model at P30 [30,31], since this
postnatal age would correspond to the age of onset of neurodevelopmental conditions in
humans. PEA treatment within the first hour of life attenuated the PA-induced alterations
at P30 such as the altered prototypical behaviors [30], as well as the biochemical and
morphological signs of altered neuronal cytoskeleton [30,31] and degeneration [30] in the
hippocampus [30] and striatum [31].
3.5. Pea and Related Enzymes and Receptors Quantitative Brain Assessment in Animal Models of
Autism, Perinatal Brain Disorders, and Stress Following Exposure to Exogenous Cannabinoids
In total, three studies did not evaluate the direct effect of PEA exposure while analyz-
ing PEA levels and indirect measures of PEA signaling in the brain of animal models of
autism and related disturbances [32–34]. A study found that alterations in various com-
ponents of the endocannabinoid system could explain the autistic-like behavior observed
among rats prenatally exposed to VPA, including increased hippocampal levels of PEA
and other ECBs/AEs in response to social exposure, altered expression and activity of the
enzymes responsible for the synthesis and catalysis of the 2-arachidonoylglycerol (2-AG)
and reduced expression of PPAR-α and GPR55 mRNA across different brain areas [32].
Similarly, another study found that the behavioral alterations observed in the PA rat model
could be due to a dysregulation of the enzymes responsible for the synthesis and catalysis
of ECBs/AEs and a reduction in the expression of PPAR-α in the hippocampus [33]. Finally,
a study found that both stress and exogenous manipulation of the endocannabinoid system
affect ECBs/AEs levels and expression of candidate genes for neuropsychiatric disorders
such as the cholinergic receptor nicotinic alpha 6 (Chrna6) and serotonin transporter neu-
rotransmitter type 4 (Slc6a4) genes, with implications for the manifestation of aberrant
behaviors [34].
4. Discussion
This is the first systematic review of all studies exploring the biobehavioral correlates
of palmitoylethanolamide (PEA) in autism spectrum disorder (ASD) in humans and ani-
mals. Previous reviews have mainly addressed the potential role of neuroinflammation
and altered glutamate signaling in ASD etiopathogenesis, indicating that, in subjects with
genetic predispositions, atypical neurodevelopment may arise from a complex interplay
between (neuro)inflammatory processes, mitochondrial dysfunction, oxidative stress and
altered expression of glutamate signaling [35]. Interestingly, research evidence converges
on the crucial role of exogenous cannabinoids and endocannabinoids in modulating such
neurobiological systems, including neuroinflammation [12] and glutamate neurotransmis-
sion [13]. Overall, this review demonstrates that PEA may be involved in ASD, as indicated
by interventional studies of the positive biobehavioral effects of PEA supplementation in
both humans and animals as well as observational studies reporting aberrancies in the PEA
signaling pathway at different levels.
PEA supplementation in humans as both monotherapy [25,26] and add-on therapy to
antipsychotic medication [27] has been shown to reduce overall autism severity [25,26] by
improving both expressive language (what the child says) [25] and inappropriate speech
(how the child says it) [27], as well as modulating atypical behavior [25–27] and immune
response [25]. Similarly, PEA supplementation in different animal models of autism and
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related conditions has been suggested to be effective in improving social and nonsocial be-
haviors [26,29,30] as well as in modulating a number of neurobiological processes including
neuroinflammation [26], neurotrophy [29], apoptosis [26], neurogenesis [26], neuroplastic-
ity [26], neurodegeneration [30,31], mitochondrial function [29], and microbiota activity [29].
Importantly, PEA administration resulted in an activation of the peroxisome proliferator
activated receptor-α (PPAR-α) [29], whose downregulation may decrease antioxidative
and anti-inflammatory processes, also altering energy homeostasis, mitochondrial fatty
acid metabolism, and regulation of genes coding proteins that are involved in glutamate
homeostasis and cholinergic/dopaminergic signaling in the brain, with implications for
neurodevelopmental conditions [36]. The hippocampus is one of the brain areas where
such modulatory effects of PEA are mostly reported. Further studies are needed to investi-
gate the role of the PEA-induced modulation of the hippocampal system in improving the
brain spatiotemporal framework within which sensory, emotional, and cognitive aspects of
an experience are processed in ASD, with implications for comprehension and language
production [37]. This is of paramount importance, as structural, functional, and neuro-
chemical alterations in the hippocampus have been suggested as candidate biomarkers for
the diagnosis of ASD in childhood [38].
Another line of research identified lower serum levels of PEA and other endocannabi-
noids (ECBs)/acylethanolamines (AEs) in humans suffering from ASD, independently
of sociodemographic and clinical characteristics [28]. Similarly, studies performed in
animal models of autism and related conditions suggested an altered response of the
PEA signaling in the face of social exposure [32], altered expression and activity of the
enzymes responsible for the synthesis and catalysis of ECBs/AEs [32,33], and downregula-
tion of PPAR-α [32,33] and the cannabinoid receptor target GPR55 mRNA expression in
the brain [32]. Interestingly, animals exposed to stress and administered with exogenous
cannabinoids showed variations in their ECB/AE levels and expression of genes implied
in neuropsychiatric disorders [34].
The findings of this systematic review have to be seen in light of some limitations.
Research in the field is still too limited, especially in humans (2 of the 4 human studies
are case reports, leaving a single experimental study conducted in a youth population
with ASD), and further studies are needed to fully address the relevance of PEA for the
different clinical phenotypes of ASD and whether the potentially beneficial effects of PEA
are mediated by a protective role of the compound against altered neuroinflammatory
responses and glutamate toxicity, which have been suggested to be involved in the patho-
physiology of ASD [7–10]. Additionally, whether the PEA concentration profile can be
used as a biomarker for ASD remains to be tested, and future longitudinal studies will
have to investigate its clinical utility in monitoring response to treatment. Moreover, as the
available evidence does not allow excluding a placebo effect [39], further clinical trials in
larger samples are needed to fully explore the efficacy and tolerability of PEA supplemen-
tation in ASD. Finally, even though the systematic review followed the PRISMA statement,
no review protocol was registered.
5. Conclusions
This review revealed a paucity of observational and experimental investigations of
PEA and its pathway in ASD. However, the 10 studies discussed here seem to converge in
reporting alterations of the PEA signaling, implications for ASD-related biobehavioral man-
ifestations, and benefits from PEA supplementation. In particular, PEA may be useful in
improving language difficulties and stereotypic behavior as well as in controlling hyperac-
tivity and irritability which co-occur frequently in ASD. Notably, no serious adverse effects
were observed with the administration of the compound in all human studies reviewed
here, making PEA supplementation a potentially valid and reasonably safe therapeutic
intervention in ASD.
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